BioMarin Pharmaceutical Inc. (BMRN) Director V Bryan Lawlis Sells 3,750 Shares of Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director V Bryan Lawlis sold 3,750 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $88.84, for a total transaction of $333,150.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

BioMarin Pharmaceutical Inc. (NASDAQ BMRN) traded down $0.08 during trading on Friday, reaching $90.24. 322,415 shares of the company’s stock were exchanged, compared to its average volume of 1,437,100. The firm has a market cap of $15,850.00, a price-to-earnings ratio of -108.72 and a beta of 1.81. BioMarin Pharmaceutical Inc. has a 12 month low of $80.10 and a 12 month high of $100.51. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.81 and a current ratio of 4.91.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The company had revenue of $334.18 million for the quarter, compared to the consensus estimate of $347.38 million. During the same period in the prior year, the firm posted $0.02 EPS. The company’s quarterly revenue was up 19.4% compared to the same quarter last year. analysts predict that BioMarin Pharmaceutical Inc. will post -0.64 EPS for the current year.

Several large investors have recently made changes to their positions in BMRN. TIAA CREF Investment Management LLC increased its position in shares of BioMarin Pharmaceutical by 63.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 2,251,011 shares of the biotechnology company’s stock valued at $204,437,000 after purchasing an additional 875,686 shares during the last quarter. Vanguard Group Inc. increased its position in shares of BioMarin Pharmaceutical by 4.7% in the 2nd quarter. Vanguard Group Inc. now owns 14,345,027 shares of the biotechnology company’s stock valued at $1,302,816,000 after purchasing an additional 642,623 shares during the last quarter. Teachers Advisors LLC increased its position in shares of BioMarin Pharmaceutical by 41.7% in the 2nd quarter. Teachers Advisors LLC now owns 973,291 shares of the biotechnology company’s stock valued at $88,394,000 after purchasing an additional 286,249 shares during the last quarter. PDT Partners LLC purchased a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at approximately $24,394,000. Finally, American Century Companies Inc. increased its position in shares of BioMarin Pharmaceutical by 64.5% in the 3rd quarter. American Century Companies Inc. now owns 614,862 shares of the biotechnology company’s stock valued at $57,225,000 after purchasing an additional 241,183 shares during the last quarter. 99.02% of the stock is currently owned by institutional investors.

BMRN has been the topic of several recent analyst reports. Piper Jaffray Companies initiated coverage on shares of BioMarin Pharmaceutical in a report on Thursday, September 14th. They issued an “overweight” rating and a $113.00 price objective on the stock. Royal Bank of Canada initiated coverage on shares of BioMarin Pharmaceutical in a report on Thursday, September 14th. They issued a “sector perform” rating and a $93.00 price objective on the stock. BMO Capital Markets restated a “buy” rating on shares of BioMarin Pharmaceutical in a report on Friday, September 15th. Jefferies Group restated a “buy” rating and issued a $116.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday, September 26th. Finally, Morgan Stanley restated an “overweight” rating and issued a $117.00 price objective (up from $115.00) on shares of BioMarin Pharmaceutical in a report on Friday, October 6th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. BioMarin Pharmaceutical has a consensus rating of “Buy” and a consensus price target of $112.44.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3127158/biomarin-pharmaceutical-inc-bmrn-director-v-bryan-lawlis-sells-3750-shares-of-stock.html.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.